DBVT · NASDAQ
DBV Technologies S.A.
$10.65 +0.53 (+5.19%)
Company overview
DBV Technologies S.A. is a clinical-stage biopharmaceutical company that engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product which has completed a Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults aged 4 to 11 years. The company is also developing Viaskin Milk, which is in a Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and a booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $255M
- Employees
- 106
- Headquarters
- Montrouge
- Website
- dbv-technologies.com
- CEO
- Daniel Tassé
- Listed
- October 22, 2014
- P/E
- -5.52
- Dividend yield
- 0.00%
Company financials
- Revenue
- $0.00
- Gross profit
- -$8.9M
- Operating income
- -$173M
- EBITDA
- -$159M
- Net income
- -$168M
- EPS
- -$1.93
- Total assets
- $266M
- Total debt
- $16.3M
- Earnings yield
- -18.12%
DBVT
1D
NASDAQ
O10.00H10.49L9.92C10.13+0.14 (+1.45%)Vol641.36K